Initial results with PD-1/PD-L1 and CTLA-4 inhibitors have been the starting point for immune-based therapy research in advanced ACC monotherapy or in combination due to the safety profile (Table 3). The gene discussed is CD274; the disease is adrenal cortex carcinoma.